EXPANDID

Extending the scope of application of intradermal vaccination

EXPANDID est accrédité par Lyonbiopôle

Identity card

Global budget: 6599 k€

Public funding: 2287 k€

Public funders: FEDER Rhône-Alpes, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Grenoble Alpes Métropole, Other (La Métro)

Call for projects: FUI (FUI AAP8)

Year start: 2009

Completed project


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Medical Technologies

Application fields: Infectious diseases

Technological approaches / Keywords: Drug delivery system

Stage of development at the beginning of the project: Preclinical development

Abstract

Based on the success of the intradermal vaccine against seasonal flu disease, the EXPAND ID project is aimed at expanding the field of applications for intradermal vaccination. The objectives are to define the injection parameters for other vaccines than flu, to precise the conditions necessary for application in the elderly population through in depth analysis of the fundamental biological events occurring in immunosenescence, to develop a micro-injection device in order to offer a simple, safe and efficient delivery system for lyophilised vaccines.  


Objectives

The objectives of the project are: - To evaluate the impact of the nature of antigen on the immune response upon ID administration - To evaluate the potential improvement of immunogenicity using vaccine formulations adapted to ID route - To investigate lyophilization process and vaccine users requirements with preliminary design input specification for the new integrated ID/reconstitution delivery system - An  cohort was enrolled in a clinical trial aiming to select non-responders elderly subjects to seasonal flu vaccine in order to investigate benefit of ID route.  


Highlights
Actual results
Perspectives

Highlights

The evaluation of the ID route for other vaccines than the flu vaccine could be interesting but required new device that BD was not able to develop. The needs to develop new formulations and the investment in manufacturing let the project not cost effective.The interest of the use of  ultra short needles ( 1.5mm long) was confirmed, without risk for the heath of users and patients vaccinated. Recrutement of a cohort of aging patients  and evaluation and understanding of the immunity and responsiveness to flu vaccine.Confirmation of the interest of the flu vaccination campaing recommended by EMEA. Development of methods for  antigenes evaluation during vaccination + high frequency cutaneous ultrasounds in small animals.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte